BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24903009)

  • 1. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.
    Folgiero V; Goffredo BM; Filippini P; Masetti R; Bonanno G; Caruso R; Bertaina V; Mastronuzzi A; Gaspari S; Zecca M; Torelli GF; Testi AM; Pession A; Locatelli F; Rutella S
    Oncotarget; 2014 Apr; 5(8):2052-64. PubMed ID: 24903009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review.
    Wells G; Kennedy PT; Dahal LN
    Front Immunol; 2021; 12():651687. PubMed ID: 33777052
    [No Abstract]   [Full Text] [Related]  

  • 3. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.
    Bonanno G; Mariotti A; Procoli A; Folgiero V; Natale D; De Rosa L; Majolino I; Novarese L; Rocci A; Gambella M; Ciciarello M; Scambia G; Palumbo A; Locatelli F; De Cristofaro R; Rutella S
    J Transl Med; 2012 Dec; 10():247. PubMed ID: 23232072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.
    Corm S; Berthon C; Imbenotte M; Biggio V; Lhermitte M; Dupont C; Briche I; Quesnel B
    Leuk Res; 2009 Mar; 33(3):490-4. PubMed ID: 18639339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells.
    Iachininoto MG; Nuzzolo ER; Bonanno G; Mariotti A; Procoli A; Locatelli F; De Cristofaro R; Rutella S
    Molecules; 2013 Aug; 18(9):10132-45. PubMed ID: 23973990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells.
    El Kholy NM; Sallam MM; Ahmed MB; Sallam RM; Asfour IA; Hammouda JA; Habib HZ; Abu-Zahra F
    Med Oncol; 2011 Mar; 28(1):270-8. PubMed ID: 20300979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations of indoleamine 2,3-dioxygenase, interferon-λ3, and anti-HBs antibodies in hemodialysis patients.
    Grzegorzewska AE; Winnicka H; Warchoł W; Mostowska A; Jagodziński PP
    Vaccine; 2018 Jul; 36(30):4454-4461. PubMed ID: 29935858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Indoleamine 2, 3-dioxygenase activity in acute myeloid leukemia cells contributing to tumor immune escape].
    Tang XQ; Zhao ZG; Wang HX; Li QB; Lü J; Zou P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):539-42. PubMed ID: 16800938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells.
    Folgiero V; Cifaldi L; Li Pira G; Goffredo BM; Vinti L; Locatelli F
    J Hematol Oncol; 2015 Apr; 8():36. PubMed ID: 25886742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
    Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
    Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia.
    Ragaini S; Wagner S; Marconi G; Parisi S; Sartor C; Nanni J; Cristiano G; Talami A; Olivi M; Ocadlikova D; Ciciarello M; Corradi G; Ottaviani E; Papayannidis C; Paolini S; Vadakekolathu J; Cavo M; Rutella S; Curti A
    Blood Adv; 2022 Jan; 6(1):87-99. PubMed ID: 34535017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's Syndrome.
    Maria NI; van Helden-Meeuwsen CG; Brkic Z; Paulissen SM; Steenwijk EC; Dalm VA; van Daele PL; Martin van Hagen P; Kroese FG; van Roon JA; Harkin A; Dik WA; Drexhage HA; Lubberts E; Versnel MA
    Arthritis Rheumatol; 2016 Jul; 68(7):1688-99. PubMed ID: 26866723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression.
    Mangaonkar A; Mondal AK; Fulzule S; Pundkar C; Park EJ; Jillella A; Kota V; Xu H; Savage NM; Shi H; Munn D; Kolhe R
    Sci Rep; 2017 Oct; 7(1):12892. PubMed ID: 29038460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-γ-induced Indoleamine 2,3-Dioxygenase Expression.
    Noh KT; Son KH; Jung ID; Kang TH; Choi CH; Park YM
    J Biol Chem; 2015 May; 290(19):12394-402. PubMed ID: 25814664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
    Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
    Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics.
    Fukuno K; Hara T; Tsurumi H; Shibata Y; Mabuchi R; Nakamura N; Kitagawa J; Shimizu M; Ito H; Saito K; Moriwaki H
    Leuk Lymphoma; 2015 May; 56(5):1398-405. PubMed ID: 25248875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia
    Atene CG; Fiorcari S; Mesini N; Alboni S; Martinelli S; Maccaferri M; Leonardi G; Potenza L; Luppi M; Maffei R; Marasca R
    Front Immunol; 2022; 13():832263. PubMed ID: 35371054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells.
    Curti A; Trabanelli S; Onofri C; Aluigi M; Salvestrini V; Ocadlikova D; Evangelisti C; Rutella S; De Cristofaro R; Ottaviani E; Baccarani M; Lemoli RM
    Haematologica; 2010 Dec; 95(12):2022-30. PubMed ID: 20801903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
    Engin AB; Engin A
    Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon γ gene transfer on interferon γ-mediated antitumor activity.
    Watcharanurak K; Zang L; Nishikawa M; Yoshinaga K; Yamamoto Y; Takahashi Y; Ando M; Saito K; Watanabe Y; Takakura Y
    Gene Ther; 2014 Sep; 21(9):794-801. PubMed ID: 24919418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.